Skip to main content
Equibles

AARTIDRUGS · Aarti Drugs Limited

Use AARTIDRUGS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AARTIDRUGS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
507.35 INR -1.40 (-0.28%) At close · Nov 13
Rebalance outlook locked
Market Cap
46.31B INR
Shares
91.27M
Volume · Nov 13 1.56M Avg daily vol (3M) 872.68K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close507.35 INR Open509.20 INR Day502.90–527.50 INR 52W close319.75–508.75 INR Avg vol 30d1.6M Last earningsNov 4, 2026 DataSep 2020–Nov 2026

Raw chart and full-history price indicators begin at the captured split on Sep 30, 2020; bars on opposite sides are not compared.

Latest documents

2026
Nov 4
Earnings call
Revenue hits record Rs. 829 crores as EBITDA rises 63%

Aarti Drugs reported Q2 FY27 revenue of Rs. 829 crores, up 27%, as EBITDA rose 63% to Rs. 138 crores and PAT increased 83% to Rs. 83 crores.

4 source passages
I am pleased to report that Q2 FY27 has been a milestone quarter for Aarti Drugs Limited. For the first time ever, our total consolidated revenue was at Rs. 829 crores in a single quarter, 27% higher than a year ago. EBITDA grew 63% to Rs. 138 crores, the highest quarterly EBITDA we have ever reported, with our EBITDA margin for the quarter reaching 16.6%, up 370 basis points year-on-year basis and the highest we have achieved in nearly 6 years. Profit after tax rose 83% to Rs. 83 crores. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▼8.1% 5.57B INR 370.50M INR '25 Q3 ▲9.2% 6.77B INR 628.60M INR '25 Q4 ▲6.3% 5.91B INR 539.10M INR '26 Q1 ▲9.1% 6.53B INR 452.80M INR '26 Q2 ▲8.1% 6.02B INR 405.40M INR '26 Q3 ▲6.4% 7.20B INR 551.90M INR '26 Q4 ▲19% 7.03B INR 501.70M INR '27 Q1 LATEST ▲26.6% 8.26B INR 829.40M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 319.75 INR Now 507.35 INR · 99% Range high 508.75 INR
vs 200-day avg +29% vs 50-day avg +18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

Raw-price comparisons begin at the captured split on Sep 30, 2020; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
XNSE:AARTIDRUGS +13.6% +28.0% +30.1% +16.6% +23.3%

Exchange listing

Market
XNSE
Ticker
AARTIDRUGS
ISIN
INE767A01016
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.aartidrugs.com/
Investor relations
https://www.aartidrugs.com/corporate-governance-disclosures-under-regulation

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-02-09 2.00 INR
2025-02-04 1.00 INR
2024-02-06 1.00 INR
2023-02-08 1.00 INR
2022-02-09 1.00 INR
2020-11-03 2.50 INR
2020-02-17 0.50 INR
2019-07-26 0.25 INR
2018-08-01 0.25 INR
2017-08-09 0.25 INR
2016-03-22 0.75 INR
2016-02-12 0.375 INR
2015-11-10 0.5625 INR
2015-08-05 0.75 INR
2014-11-19 0.625 INR
2013-11-19 0.375 INR
2013-07-24 0.50 INR
2013-02-11 0.375 INR
2012-11-05 0.375 INR
2012-02-06 0.25 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-04 Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-08-03 Transcript
    Earnings Call for the Quarter Ended June 30, 2026
  • Earnings call · Q4 2026 2026-05-18 Transcript
    Earnings Call for the Quarter Ended March 31, 2026